- Home
- NOTV vs ZURA Comparison
NOTV vs ZURA Comparison
Compare NOTV & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- ZURA
- Stock Information
- Founded
- NOTV 1974
- ZURA 2022
- Country
- NOTV United States
- ZURA United States
- Employees
- NOTV N/A
- ZURA N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NOTV Health Care
- ZURA Health Care
- Exchange
- NOTV Nasdaq
- ZURA Nasdaq
- Market Cap
- NOTV 62.5M
- ZURA 69.9M
- IPO Year
- NOTV 1997
- ZURA N/A
- Fundamental
- Price
- NOTV $2.00
- ZURA $1.31
- Analyst Decision
- NOTV Strong Buy
- ZURA Buy
- Analyst Count
- NOTV 1
- ZURA 7
- Target Price
- NOTV $5.00
- ZURA $14.33
- AVG Volume (30 Days)
- NOTV 512.6K
- ZURA 708.2K
- Earning Date
- NOTV 08-07-2025
- ZURA 08-08-2025
- Dividend Yield
- NOTV N/A
- ZURA N/A
- EPS Growth
- NOTV N/A
- ZURA N/A
- EPS
- NOTV N/A
- ZURA N/A
- Revenue
- NOTV $480,402,000.00
- ZURA N/A
- Revenue This Year
- NOTV $4.99
- ZURA N/A
- Revenue Next Year
- NOTV $5.39
- ZURA N/A
- P/E Ratio
- NOTV N/A
- ZURA N/A
- Revenue Growth
- NOTV N/A
- ZURA N/A
- 52 Week Low
- NOTV $1.15
- ZURA $0.97
- 52 Week High
- NOTV $6.48
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- NOTV 49.04
- ZURA 59.63
- Support Level
- NOTV $2.06
- ZURA $1.00
- Resistance Level
- NOTV $2.30
- ZURA $1.45
- Average True Range (ATR)
- NOTV 0.17
- ZURA 0.10
- MACD
- NOTV 0.02
- ZURA 0.03
- Stochastic Oscillator
- NOTV 70.31
- ZURA 68.89
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.